These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1118 related articles for article (PubMed ID: 16984553)

  • 1. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
    Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study.
    Komiya A; Suzuki H; Awa Y; Egoshi K; Onishi T; Nakatsu H; Ohki T; Mikami K; Sato N; Araki K; Ota S; Naya Y; Ichikawa T
    Int J Urol; 2010 Jun; 17(6):555-62. PubMed ID: 20370847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamsulosin: effect on quality of life in 2740 patients with lower urinary tract symptoms managed in real-life practice in Spain.
    Batista JE; Palacio A; Torrubia R; Hernández C; Vicente J; Resel L;
    Arch Esp Urol; 2002; 55(1):97-105. PubMed ID: 11957763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report.
    Palacio A; Hernández C; Marqués A; Prats J; Espinosa FJ
    Arch Esp Urol; 2004 May; 57(4):451-60. PubMed ID: 15270291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
    Barkin J; Roehrborn CG; Siami P; Haillot O; Morrill B; Black L; Montorsi F;
    BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment outcome of tamsulosin for benign prostatic hyperplasia.
    Ichioka K; Ohara H; Terada N; Matsui Y; Yoshimura K; Terai A; Arai Y
    Int J Urol; 2004 Oct; 11(10):870-5. PubMed ID: 15479292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment.
    Awa Y; Suzuki H; Hamano S; Okano T; Sakurayama Y; Ohki T; Egoshi K; Ota S; Mori I; Ichikawa T
    Int J Urol; 2008 Aug; 15(8):709-15. PubMed ID: 18662175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms.
    Barqawi AB; Myers JB; O'Donnell C; Crawford ED
    BJU Int; 2007 Oct; 100(4):853-7. PubMed ID: 17662074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
    Te AE; Malloy TR; Stein BS; Ulchaker JC; Nseyo UO; Hai MA
    BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change in urinary symptoms and quality of life in men with benign prostatic hyperplasia after transurethral resection of prostate.
    Chalise PR; Agrawal CS
    Nepal Med Coll J; 2007 Dec; 9(4):255-8. PubMed ID: 18298015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
    Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
    BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.
    Tsai YS; Lan SK; Ou JH; Tzai TS
    Clin Ther; 2007 Apr; 29(4):670-82. PubMed ID: 17617290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of transurethral resection of prostate on the quality of life of patients with benign prostatic hyperplasia.
    O'Sullivan M; Murphy C; Deasy C; Iohom G; Kiely EA; Shorten G
    J Am Coll Surg; 2004 Mar; 198(3):394-403. PubMed ID: 14992742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Impact of Solifenacin on Generic and Symptom-Specific Quality of Life for Females with Overactive Bladder: Using the Overactive Bladder Symptom Score and Rand Medical Outcomes Study 36-Item Health Survey.
    Yano M; Suzuki H; Kamiya N; Kato T; Nomura K; Kuramochi H; Ohta S; Mikami K; Nakatsu H; Okano T; Onishi T; Ichikawa T
    Low Urin Tract Symptoms; 2013 Jan; 5(1):5-10. PubMed ID: 26663241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
    Lukacs B; Leplège A; Thibault P; Jardin A
    Urology; 1996 Nov; 48(5):731-40. PubMed ID: 8911517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.